Japan announces plans for pioneering genetically modified pig kidney transplant into humans

A Japanese company, PorMedTec, in partnership with Hokkaido University and the Tokushukai medical group, reported this Monday (3) that it plans the first national clinical trial of pig kidney transplantation with genetic modifications. The announcement marks a significant step in the advancement of medicine in the country.
The intention is to take advantage of the advances of the North American group eGenesis, considered a global reference, to establish the basis for the clinical application of kidney xenotransplantation in Japan, as detailed by PorMedTec in its statement. This type of procedure, which involves transferring organs between different species, is seen as a significant hope for patients awaiting donations, given the global shortage of human organs.
Testing is scheduled to begin in 2028, pending prior approval from Japanese health authorities to proceed with the project. Obtaining these permissions is a fundamental step to guarantee the safety and ethics of the process.
To make the initiative viable, PorMedTec plans to clone donor pigs developed by eGenesis in Japan, which have 69 genetic modifications. These changes are crucial to reduce the risk of rejection of the organ by the human recipient and prevent the possible transmission of swine viruses, central challenges in the field of xenotransplantation that seek to make the procedure safer.
To date, the North American company eGenesis has already performed four similar transplants on patients, showing the potential and evolution of this innovative technology and paving the way for research like the Japanese one.







